Analysts expect Heska Corp (NASDAQ:HSKA) to post $0.35 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Heska’s earnings, with the lowest EPS estimate coming in at $0.32 and the highest estimate coming in at $0.37. Heska reported earnings of $0.40 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 12.5%. The company is expected to issue its next earnings results on Thursday, November 1st.
According to Zacks, analysts expect that Heska will report full-year earnings of $1.67 per share for the current fiscal year, with EPS estimates ranging from $1.62 to $1.72. For the next financial year, analysts expect that the business will post earnings of $2.00 per share, with EPS estimates ranging from $1.99 to $2.00. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Heska.
Heska (NASDAQ:HSKA) last posted its earnings results on Tuesday, August 7th. The medical research company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.07. The company had revenue of $29.66 million during the quarter, compared to analyst estimates of $30.19 million. Heska had a net margin of 4.67% and a return on equity of 11.49%.
HSKA has been the subject of a number of analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $123.00 target price (up from $115.00) on shares of Heska in a report on Friday, June 15th. ValuEngine lowered shares of Heska from a “buy” rating to a “hold” rating in a report on Thursday, June 21st. BidaskClub lowered shares of Heska from a “strong-buy” rating to a “buy” rating in a report on Friday, June 22nd. Zacks Investment Research upgraded shares of Heska from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 18th. Finally, Benchmark initiated coverage on shares of Heska in a report on Thursday, July 19th. They set a “buy” rating and a $120.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Heska presently has an average rating of “Hold” and an average target price of $107.50.
In other Heska news, EVP Steven M. Eyl sold 33,351 shares of the firm’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $98.49, for a total value of $3,284,739.99. Following the completion of the sale, the executive vice president now directly owns 15,401 shares in the company, valued at $1,516,844.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Steven M. Eyl sold 1,051 shares of the firm’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $98.00, for a total transaction of $102,998.00. Following the completion of the sale, the executive vice president now owns 15,401 shares of the company’s stock, valued at $1,509,298. The disclosure for this sale can be found here. Insiders sold 59,028 shares of company stock valued at $5,986,060 over the last 90 days. 15.90% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Heska by 10.6% in the second quarter. BlackRock Inc. now owns 1,027,636 shares of the medical research company’s stock worth $106,657,000 after buying an additional 98,875 shares during the period. FMR LLC lifted its holdings in Heska by 81.9% in the second quarter. FMR LLC now owns 459,211 shares of the medical research company’s stock worth $47,662,000 after buying an additional 206,814 shares during the period. Redmile Group LLC lifted its holdings in Heska by 48.8% in the second quarter. Redmile Group LLC now owns 354,776 shares of the medical research company’s stock worth $36,822,000 after buying an additional 116,330 shares during the period. Fred Alger Management Inc. lifted its holdings in Heska by 157.4% in the second quarter. Fred Alger Management Inc. now owns 277,687 shares of the medical research company’s stock worth $28,821,000 after buying an additional 169,804 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in Heska by 8.5% in the second quarter. Janus Henderson Group PLC now owns 241,885 shares of the medical research company’s stock worth $25,105,000 after buying an additional 18,983 shares during the period. Institutional investors and hedge funds own 89.15% of the company’s stock.
Shares of Heska stock traded down $3.64 during trading on Friday, reaching $100.15. 56,281 shares of the stock were exchanged, compared to its average volume of 70,415. The firm has a market cap of $849.58 million, a P/E ratio of 48.38 and a beta of 0.50. Heska has a 1 year low of $56.59 and a 1 year high of $114.50.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Featured Story: Short Selling Stocks, A Beginner’s Guide
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.